Kevin DeGeeter
Stock Analyst at Oppenheimer
(2.81)
# 1,808
Out of 4,876 analysts
44
Total ratings
35.29%
Success rate
52.25%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.08 | +1,946.51% | 1 | Apr 19, 2022 | |
| ORIC ORIC Pharmaceuticals | Downgrades: Perform | n/a | $10.32 | - | 1 | Mar 22, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $6.46 | +271.52% | 4 | Feb 25, 2022 | |
| NVCR NovoCure | Upgrades: Outperform | $98 | $18.02 | +443.99% | 3 | Feb 2, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $19.61 | +537.43% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $2.29 | +686.03% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $3.96 | +379.80% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $2.96 | - | 1 | Oct 1, 2021 | |
| PRTG Portage Biotech | Initiates: Outperform | $600 | $5.61 | +10,595.19% | 1 | Sep 21, 2021 | |
| PANW Palo Alto Networks | Maintains: Outperform | $75 → $79 | $200.48 | -60.51% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $53.66 | +188.86% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $8.68 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.35 | +474.71% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4,080 | $0.33 | +1,228,815.66% | 1 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $2.44 | +73,670.49% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $41.72 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.40 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.53 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $7.97 | +527.35% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $3.28 | +27,339.02% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $6.36 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $16.60 | +893.98% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $49.33 | +356.11% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $5.25 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.39 | - | 2 | Jan 4, 2017 |
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.08
Upside: +1,946.51%
ORIC Pharmaceuticals
Mar 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $10.32
Upside: -
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $6.46
Upside: +271.52%
NovoCure
Feb 2, 2022
Upgrades: Outperform
Price Target: $98
Current: $18.02
Upside: +443.99%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $19.61
Upside: +537.43%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $2.29
Upside: +686.03%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $3.96
Upside: +379.80%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.96
Upside: -
Portage Biotech
Sep 21, 2021
Initiates: Outperform
Price Target: $600
Current: $5.61
Upside: +10,595.19%
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $200.48
Upside: -60.51%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $53.66
Upside: +188.86%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $8.68
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $4.35
Upside: +474.71%
Apr 30, 2021
Initiates: Outperform
Price Target: $4,080
Current: $0.33
Upside: +1,228,815.66%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $2.44
Upside: +73,670.49%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $41.72
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.40
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $2.53
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $50
Current: $7.97
Upside: +527.35%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $3.28
Upside: +27,339.02%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $6.36
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $16.60
Upside: +893.98%
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $49.33
Upside: +356.11%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $5.25
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $2.39
Upside: -